Perrigo Q2 2026 sales fall 3.2%, adjusted EPS drops 12.3%; full-year outlook reaffirmed
Perrigo reported second-quarter 2026 All In net sales of $1,023 million, down 3.2% from a year earlier, and All In adjusted diluted EPS of $0.50, down 12.3%. Reported diluted EPS was $0.63, helped by a gain on the Dermacosmetics sale, and the company reaffirmed its full-year 2026 All In adjusted EPS range of $2.00 to $2.30. For shareholders, the headline sales and adjusted profit measures declined, while the outlook was held rather than cut.
Key points
- All In net sales were $1,023 million versus $1,056 million; Core net sales were $907 million, down 3.1%.
- All In adjusted diluted EPS was $0.50 versus $0.57; Core adjusted diluted EPS was $0.46 versus $0.58.
- Reported diluted EPS was $0.63 versus $0.00, benefiting from the gain on the Dermacosmetics divestiture, which closed in the quarter.
- Full-year 2026 All In adjusted EPS outlook of $2.00 to $2.30 was reaffirmed; cash and equivalents were $400 million and total debt $3.3 billion as of June 27, 2026.
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.